BRPI0517909B8 - cloridrato de (s)-(-)-1-(4-fluorisoquinolin-5-il)sulfonil-2-metil-1,4-homopiperazino diidratado - Google Patents

cloridrato de (s)-(-)-1-(4-fluorisoquinolin-5-il)sulfonil-2-metil-1,4-homopiperazino diidratado

Info

Publication number
BRPI0517909B8
BRPI0517909B8 BRPI0517909A BRPI0517909A BRPI0517909B8 BR PI0517909 B8 BRPI0517909 B8 BR PI0517909B8 BR PI0517909 A BRPI0517909 A BR PI0517909A BR PI0517909 A BRPI0517909 A BR PI0517909A BR PI0517909 B8 BRPI0517909 B8 BR PI0517909B8
Authority
BR
Brazil
Prior art keywords
fluoroisoquinolin
sulfonyl
methyl
homopiperazine hydrochloride
dihydrate
Prior art date
Application number
BRPI0517909A
Other languages
English (en)
Inventor
Hidaka Hiroyoshi
Onogi Kazuhiro
Shiratsuchi Masami
Ohshima Takeshi
Oda Toshiaki
Original Assignee
D Western Therapeutics Inst Inc
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36498130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0517909(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by D Western Therapeutics Inst Inc, Kowa Co filed Critical D Western Therapeutics Inst Inc
Publication of BRPI0517909A publication Critical patent/BRPI0517909A/pt
Publication of BRPI0517909B1 publication Critical patent/BRPI0517909B1/pt
Publication of BRPI0517909B8 publication Critical patent/BRPI0517909B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

cloridrato de (s)-(-)-1-(4-fluorisoquinolin-5-il) sulfonil-2-metil-1,4-homopiperazino diidratado cloridrato de (s)-(-)-1-(4-fluorisoquinolin-5-i1) sulfonil-2-metil-1,4-homopiperazino diidratado; um processo para produzir o diidrato e uma composição medicinal contendo o diidrato. este composto possui menor higroscopicidade do que os cristais anidros de cloridrato de (s)-(-)-1-(4-fluorisoquinolin-5-il)sulfonil-2-metil-1,4-homopiperazino diidratado e é superior na estabilidade química, sendo por isso, útil como um medicamento.
BRPI0517909A 2004-11-29 2005-11-29 cloridrato de (s)-(-)-1-(4-fluorisoquinolin-5-il)sulfonil-2-metil-1,4-homopiperazino diidratado BRPI0517909B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004344271 2004-11-29
PCT/JP2005/021844 WO2006057397A1 (ja) 2004-11-29 2005-11-29 （ｓ）－（－）－１－（４－フルオロイソキノリン－５－イル）スルホニル－２－メチル－１，４－ホモピペラジン塩酸塩・二水和物

Publications (3)

Publication Number Publication Date
BRPI0517909A BRPI0517909A (pt) 2008-10-21
BRPI0517909B1 BRPI0517909B1 (pt) 2018-11-21
BRPI0517909B8 true BRPI0517909B8 (pt) 2021-05-25

Family

ID=36498130

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517909A BRPI0517909B8 (pt) 2004-11-29 2005-11-29 cloridrato de (s)-(-)-1-(4-fluorisoquinolin-5-il)sulfonil-2-metil-1,4-homopiperazino diidratado

Country Status (23)

Country Link
US (1) US7858615B2 (pt)
EP (1) EP1818329B1 (pt)
JP (1) JP4016060B2 (pt)
KR (1) KR101253369B1 (pt)
CN (1) CN101068806B (pt)
AT (1) ATE465159T1 (pt)
AU (1) AU2005308060B2 (pt)
BR (1) BRPI0517909B8 (pt)
CA (1) CA2589237C (pt)
CY (1) CY1112406T1 (pt)
DE (1) DE602005020835D1 (pt)
DK (1) DK1818329T3 (pt)
EA (1) EA011283B1 (pt)
ES (1) ES2345562T3 (pt)
MX (1) MX2007006322A (pt)
MY (1) MY139797A (pt)
NO (1) NO339021B1 (pt)
NZ (1) NZ555560A (pt)
PL (1) PL1818329T3 (pt)
PT (1) PT1818329E (pt)
TW (1) TWI354670B (pt)
WO (1) WO2006057397A1 (pt)
ZA (1) ZA200704201B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006290827A (ja) * 2005-04-13 2006-10-26 Kowa Co 緑内障予防又は治療剤
CA2621181C (en) * 2005-08-30 2011-04-19 Asahi Kasei Pharma Corporation 5-isoquinolinesulfonamide compounds
US8415372B2 (en) * 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
ES2396795T3 (es) 2007-07-02 2013-02-27 Asahi Kasei Pharma Corporation Compuesto de sulfonamida y cirstal del mismo
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
WO2012026529A1 (ja) 2010-08-26 2012-03-01 興和株式会社 イソキノリン誘導体又はその塩の新規製造方法
JP5557408B1 (ja) * 2013-04-24 2014-07-23 国立大学法人九州大学 眼底疾患治療剤
PL3199161T3 (pl) * 2014-09-25 2022-04-11 Kowa Company, Ltd. Preparat farmaceutyczny
US10369781B2 (en) * 2015-01-08 2019-08-06 Hewlett-Packard Development Company, L.P. Mobile printers
CN107216311B (zh) * 2016-03-21 2019-09-03 山东诚创医药技术开发有限公司 (s)-4-[(4-氟代异喹啉-5-基)磺酰基]-3-甲基-1,4-二氮杂环庚烷盐酸盐的精制方法
CN106496189A (zh) * 2016-10-10 2017-03-15 江苏礼华生物技术有限公司 盐酸Ripasudil晶型
CN107164328A (zh) * 2017-06-30 2017-09-15 太仓卡斯特姆新材料有限公司 一种高稳定性mcf‑7乳腺癌细胞的复苏方法
CA3120751A1 (en) 2018-12-17 2020-06-25 D. Western Therapeutics Institute, Inc. New form of isoquinoline sulfonamide
JP7398137B2 (ja) 2019-06-21 2023-12-14 コアンチョウ オキュサン オフサルミック バイオテクノロジー カンパニー リミテッド Ｒｏｃｋプロテインキナーゼ阻害薬としてのイソキノリンの誘導体及びその使用
CN114644618A (zh) * 2020-12-21 2022-06-21 广州润尔眼科生物科技有限公司 一种作为rock蛋白激酶抑制剂的异喹啉酮型化合物的盐型及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3734531B2 (ja) 1995-06-29 2006-01-11 旭化成ファーマ株式会社 １−（５−イソキノリンスルホニル）ホモピペラジン塩酸塩３水和物
CN1080721C (zh) 1995-07-03 2002-03-13 旭化成株式会社 1－(5－异喹啉磺酰基)高哌嗪盐酸盐水合物
ES2205166T3 (es) * 1996-02-02 2004-05-01 D. Western Therapeutics Institute Derivados de isoquinolina y medicamento.
AU9646198A (en) * 1997-10-22 1999-05-10 Nippon Shinyaku Co. Ltd. Isoquinoline derivative and drug

Also Published As

Publication number Publication date
EP1818329B1 (en) 2010-04-21
MY139797A (en) 2009-10-30
JP4016060B2 (ja) 2007-12-05
KR101253369B1 (ko) 2013-04-11
ATE465159T1 (de) 2010-05-15
ZA200704201B (en) 2008-09-25
AU2005308060B2 (en) 2011-02-17
NZ555560A (en) 2008-10-31
EP1818329A4 (en) 2009-08-05
WO2006057397A1 (ja) 2006-06-01
BRPI0517909B1 (pt) 2018-11-21
PT1818329E (pt) 2010-06-22
KR20070084127A (ko) 2007-08-24
DK1818329T3 (da) 2010-07-19
DE602005020835D1 (de) 2010-06-02
CN101068806B (zh) 2012-02-01
BRPI0517909A (pt) 2008-10-21
AU2005308060A1 (en) 2006-06-01
HK1112898A1 (en) 2008-09-19
US20080021018A1 (en) 2008-01-24
ES2345562T3 (es) 2010-09-27
EA011283B1 (ru) 2009-02-27
CN101068806A (zh) 2007-11-07
PL1818329T3 (pl) 2010-10-29
EP1818329A1 (en) 2007-08-15
US7858615B2 (en) 2010-12-28
NO20072382L (no) 2007-08-23
EA200701156A1 (ru) 2007-10-26
CY1112406T1 (el) 2015-12-09
CA2589237C (en) 2013-05-14
TWI354670B (en) 2011-12-21
JPWO2006057397A1 (ja) 2008-06-05
TW200630359A (en) 2006-09-01
NO339021B1 (no) 2016-11-07
MX2007006322A (es) 2007-06-19
CA2589237A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
CY1112406T1 (el) Διενυδρη υδροχλωρικη (s)-(-)-1-(4-φθοροϊσοκινολιν-5-υλ)σουλφονυλ-2-μεθυλ-1,4-ομοπιπεραζινη
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
DK1628685T3 (da) Antivirale phosphonatanaloge
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
EA200702670A1 (ru) Препарат тиенопиридинового ингибитора агрегации тромбоцитов
CR9421A (es) Compuestos heterociclicos fusionados
EA200870460A1 (ru) Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
EA200600317A1 (ru) Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
DK1756052T3 (da) Forbedret fremgangsmåde til at fremstille 3-hydroxy-4-hydroxymethyl-pyrrolidin-forbindelser
ATE553077T1 (de) Peptidaseinhibitoren
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
ATE495158T1 (de) Substituierte tetrahydroisochinoline als mmp- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
DK1723140T3 (da) Fremgangsmåde til fremstilling af tryptase-inhibitorer
ATE334980T1 (de) Verfahren zur herstellung von 2-methyl piperazine derivaten.
ATE423775T1 (de) Verfahren zur herstellung von lactonen
DE602004006021D1 (de) Verfahren zur racematspaltung von nefopam
SE0403003D0 (sv) Chemical compound 1
GB0314299D0 (en) Chemical compounds
UA93030C2 (ru) Способ получения клопидогрела (варианты) и промежуточные соединения

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2750 DE 19-09-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.